🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This stems from revelations that a much-touted deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond broad headline terms contained within government press releases.

Lacking Legal Footing

The arrangement concerning medicines, described as a "landmark" achievement, remains an "agreement in principle" without a signed legal text. Observers point out that the public statements from the UK and US governments describe the deal in markedly contrasting terms. The British version emphasizes securing "zero per cent tariffs" as a unique achievement, while the American announcement highlights the agreement for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for only a assurance from President Trump," commented David Henig, a trade policy analyst. "It is documented he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been intensified by Washington's recent decision to suspend the major technology agreement, which was previously described as "a generational step-change" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an initial accord have not been formally approved by the US, despite a imminent January deadline. "It is our belief that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have admitted unease that the government's deals with Washington are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "The only thing more surprising than the US approach is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have attempted to minimize the chances of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials acknowledge that unpredictability is a feature of dealing with the Trump administration. However, they contend that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, problems have arisen in implementing the initial US-UK accord. Promised quotas on beef exports have yet to be finalized, and the pledge to "reduce steel tariffs to zero" has not been fulfilled, with tariffs remaining at 25%.

Looking ahead, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.